HomeInsightsStock Comparison

Abbott India Ltd vs Zydus Lifesciences Ltd Stock Comparison

Abbott India Ltd vs Zydus Lifesciences Ltd Stock Comparison

Last Updated on: May 17, 2025

Key Highlights

  • The Latest Trading Price of Abbott India Ltd is ₹ 30560 as of 16 May 15:30.
  • The P/E Ratio of Abbott India Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 26.2 on March 2024 . This represents a CAGR of 2.37% over 5 years.
  • The Market Cap of Abbott India Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 27344 crore on March 2020 to ₹ 101151 crore on March 2024 . This represents a CAGR of 29.90% over 5 years.
  • The revenue of Abbott India Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Zydus Lifesciences Ltd for the Dec '24 is ₹ 5326 crore as compare to the Sep '24 revenue of ₹ 5305 crore. This represent the growth of 0.4%.
  • The ebitda of Abbott India Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Zydus Lifesciences Ltd for the Dec '24 is ₹ 1444 crore as compare to the Sep '24 ebitda of ₹ 1529 crore. This represent the decline of -5.56%.
  • The net profit of Abbott India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Zydus Lifesciences Ltd changed from ₹ 1112 crore to ₹ 1004 crore over 7 quarters. This represents a CAGR of -5.66% .
  • The Dividend Payout of Abbott India Ltd changed from 89.6 % on March 2020 to 72.53 % on March 2024 . This represents a CAGR of -4.14% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 25.37 % on March 2020 to 8.77 % on March 2024 . This represents a CAGR of -19.14% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Abbott India Ltd

  • Abbott India Ltd. is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country.
  • The Company sells its products through independent distributors primarily within India.
  • It provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc.
  • Its global products include Brufen, Prothiaden, Thyronorm and Leptos. The company has four divisions.
  • The Primary Care division markets products in the areas of pain management and gastroenterology.

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Abbott India Ltd News Hub

News

Abbott India AGM scheduled

Abbott India announced that the 81th Annual General Meeting(AGM) of the company will be he...

Read more

16 May 2025 09:25

News

Board of Abbott India recommends final dividend

Abbott India announced that the Board of Directors of the Company at its meeting held on 1...

Read more

16 May 2025 09:25

News

Abbott India rises after Q4 PAT jumps 28% YoY to Rs 367 cr; declares dividend of Rs 475 /sh

Profit before tax (PBT) stood at Rs 482.71 crore in Q4 FY25, up 23.9% YoY. Total expenses ...

Read more

16 May 2025 10:58

News

Abbott India to conduct board meeting

Abbott India will hold a meeting of the Board of Directors of the Company on 15 May 2025. ...

Read more

07 May 2025 14:26

News

Abbott India appoints senior management personnel

Abbott India has appointed Anushree Kunhambu - Associate Director - New Product Introducti...

Read more

16 Apr 2025 09:38

News

Abbott India announces resignation of senior management personnel

Abbott India announced the resignation of Namita Shah - Associate Director - New Product I...

Read more

16 Apr 2025 14:57

Zydus Lifesciences Ltd News Hub

News

Zydus Lifes receives EIR for the Ambernath manufacturing facility

The inspection was conducted by the USFDA from 10 February to 14 February 2025 and conclud...

Read more

14 May 2025 14:16

News

Zydus Lifesciences receives EIR for its API manufacturing facility at Ambernath

Zydus Lifesciences has received the EIR report from the USFDA for the inspection conducted...

Read more

14 May 2025 15:28

News

Zydus Lifesciences schedules board meeting

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 20 May ...

Read more

10 May 2025 11:06

News

Zydus Life gets US FDA nod for MS treatment drug Glatiramer Acetate

The Glatiramer Acetate Injection is an AP-rated substitutable generics of Copaxone, 20 mg/...

Read more

09 May 2025 09:21

News

Zydus Life gains after USFDA approval for Niacin Extended-Release tablets

The approved medication is indicated for the treatment of patients with primary hyperlipid...

Read more

30 Apr 2025 11:32

News

Zydus receives USFDA approval for Niacin Extended-Release Tablets

Zydus Lifesciences has received final approval from the United States Food and Drug Admini...

Read more

30 Apr 2025 14:52

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

SWOT Analysis Of Abbott India Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Abbott India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Abbott India Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Abbott India Ltd or Zydus Lifesciences Ltd?

Market cap of Abbott India Ltd is 64,941 Cr while Market cap of Zydus Lifesciences Ltd is 90,862 Cr

What are the key factors driving the stock performance of Abbott India Ltd and Zydus Lifesciences Ltd?

The stock performance of Abbott India Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Abbott India Ltd and Zydus Lifesciences Ltd?

As of May 17, 2025, the Abbott India Ltd stock price is INR ₹30560.85. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹903.0.

How do dividend payouts of Abbott India Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Abbott India Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions